2024
Patterns of CNS Failures in Relapse/Refractory Large B-Cell Lymphoma (LBCL) Patients with Secondary CNS Disease Following Chimeric Antigen Receptor T-Cell (CAR T) Therapy
Nakashima J, Khatri V, Cruz-Chamorro R, Zhou J, Patra P, Gaballa S, Khimani F, Mirza S, Shah B, Saeed H, Chavez J, Locke F, Nishihori T, Liu H, Dong N, Lazaryan A, Robinson T, Freeman C, Jain M, Figura N. Patterns of CNS Failures in Relapse/Refractory Large B-Cell Lymphoma (LBCL) Patients with Secondary CNS Disease Following Chimeric Antigen Receptor T-Cell (CAR T) Therapy. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e646-e647. DOI: 10.1016/j.ijrobp.2024.07.1421.Peer-Reviewed Original ResearchLarge B-cell lymphomaSecondary CNS lymphomaB-cell lymphomaCNS failureCNS recurrenceCNS diseaseCNS lymphomaCAR-TOverall survivalBridging therapyCNS diagnosisRelapsed/refractory large B-cell lymphomaChimeric antigen receptor T cellsCAR-T cell trialsPattern of failure analysisCAR-T cell therapyMedian age of patientsClinical outcomes of patientsCNS-only progressionSystemic disease recurrenceT-cell therapyCAR-T therapyCytokine-release syndromePatterns of recurrenceKaplan-Meier method
2023
Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: An ILROG Multi-Institutional Study
Yegya-Raman N, Wright C, Ladbury C, Chew J, Zhang S, Sun S, Burke S, Baron J, Sim A, LaRiviere M, Yang J, Robinson T, Tseng Y, Terezakis S, Braunstein S, Dandapani S, Schuster S, Chong E, Plastaras J, Figura N. Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: An ILROG Multi-Institutional Study. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: s50-s51. DOI: 10.1016/j.ijrobp.2023.06.333.Peer-Reviewed Original ResearchImmune effector cell-associated neurotoxicity syndromeProgression-free survivalCytokine release syndromeB-cell lymphomaChimeric antigen receptor T-cell therapySuperior progression-free survivalLarge B-cell lymphomaCAR-T infusionT-cell therapyMulti-institutional studyOverall survivalCTCAE v5.0T infusionTisa-celCAR TRefractory aggressive B-cell lymphomasStage III/IV diseaseT-cell/histiocyte-rich large B-cell lymphomaFavorable progression-free survivalCentral nervous system involvementDiffuse large B-cell lymphomaAggressive B-cell lymphomasPrimary mediastinal B-cell lymphomaMediastinal B-cell lymphomaNervous system involvementEpstein‑Barr virus‑associated primary central nervous system lymphoma in an immunosuppressed patient with a comorbid autoimmune disorder: A case report
Bricoune O, Kareem S, Wallace G, Iacono D, Macaulay R, Etame A, Pina Y, Robinson T, Mokhtari S. Epstein‑Barr virus‑associated primary central nervous system lymphoma in an immunosuppressed patient with a comorbid autoimmune disorder: A case report. Experimental And Therapeutic Medicine 2023, 26: 410. PMID: 37522053, PMCID: PMC10375448, DOI: 10.3892/etm.2023.12109.Peer-Reviewed Original ResearchPrimary central nervous system lymphomaEpstein-Barr virusCentral nervous system lymphomaDiffuse large B-cell lymphomaNervous system lymphomaMycophenolate mofetilMemory lossSystem lymphomaPeriventricular lesionsEnhancing lesionsBrain MRIEpstein-Barr virus-associated primary central nervous system lymphomaAcetylcholine receptor antibody-positive myasthenia gravisNon-focal neurological symptomsSubsequent chronic kidney diseaseVaricella zoster virus (VZV) vasculopathyAntibody-positive myasthenia gravisWhole-brain radiation therapyLarge B-cell lymphomaComorbid autoimmune disordersLeft eye visionRepeat brain MRIHigh-dose methotrexateVaricella zoster infectionChronic kidney disease
2022
Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes
Figura N, Sim A, Jain M, Chavez J, Robinson T. Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes. Expert Review Of Hematology 2022, 15: 1023-1030. PMID: 36369950, DOI: 10.1080/17474086.2022.2147919.Peer-Reviewed Original ResearchConceptsCAR T-cell therapyT-cell therapySalvage radiotherapyPatient outcomesAnti-CD19 chimeric antigen receptor (CAR) T-cell therapyChimeric antigen receptor T-cell therapyLarge B-cell lymphomaCurrent retrospective dataHigh tumor burdenClinical risk factorsAblative radiation dosesHypothesis-driven clinical trialsB-cell lymphomaMost patientsR DLBCLLocal recurrenceTumor burdenClinical evidenceRisk factorsTreatment paradigmClinical trialsTreatment outcomesRadiation therapyElevated riskPatientsPatient-Level Disease Burden as a Predictor of In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas
Figura N, Sim A, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu H, Christopherson K, Kim S, Locke F, Jain M, Robinson T. Patient-Level Disease Burden as a Predictor of In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: s85. DOI: 10.1016/j.ijrobp.2022.07.491.Peer-Reviewed Original ResearchMedian metabolic tumor volumeT-cell therapyRefractory large B-cell lymphomaCAR T-cell therapyLarge B-cell lymphomaBRT patientsDisease burdenTotal disease burdenB-cell lymphomaField progressionRadiation therapyLocal controlClinical outcomesExact testChimeric antigen receptor T-cell therapyCAR T-cell infusionDistant-only failureDurable local controlLocal-only failureWorse disease burdenFuture prospective trialsT-cell infusionHigh-risk patientsKaplan-Meier methodLow disease burden
2021
NCMP-08. CHALLENGING DIAGNOSIS AND MANAGEMENT OF PCNSL IN AN IMMUNOSUPPRESSED PATIENT ON MYCOPHENOLATE MOFETIL FOR MYASTHENIA GRAVIS
Bricoune O, Mokhtari S, Etame A, Robinson T, Pina Y, Macaulay R. NCMP-08. CHALLENGING DIAGNOSIS AND MANAGEMENT OF PCNSL IN AN IMMUNOSUPPRESSED PATIENT ON MYCOPHENOLATE MOFETIL FOR MYASTHENIA GRAVIS. Neuro-Oncology 2021, 23: vi148-vi149. DOI: 10.1093/neuonc/noab196.581.Peer-Reviewed Original ResearchPrimary CNS lymphomaDiffuse large B-cell lymphomaMycophenolate mofetilMyasthenia gravisEnhancing lesionsBrain MRIAcetylcholine receptor antibody-positive myasthenia gravisDiagnosis of PCNSLManagement of PCNSLAntibody-positive myasthenia gravisLarge B-cell lymphomaLeft eye visionRepeat brain MRIFocal neurological deficitsCerebrospinal fluid analysisPositive myasthenia gravisGross total resectionPeriventricular white matterLeft frontal lesionNew enhancing lesionsAdditional diagnostic testsB-cell lymphomaLeft medullaOral prednisoneRituximab IVIn-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas
Sim A, Figura N, Dohm A, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu H, Kim S, Locke F, Jain M, Robinson T. In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s131. DOI: 10.1016/j.ijrobp.2021.07.297.Peer-Reviewed Original ResearchMetabolic tumor volumeRefractory large B-cell lymphomaCAR T-cell infusionLarge B-cell lymphomaT-cell infusionT-cell therapyB-cell lymphomaTreatment failureChimeric antigen receptor T-cell therapyField local control rateCAR T-cell therapyBaseline PET/CTLocal failureCAR-T infusionExperience disease progressionLower RT dosesDisease-free survivalLocal control rateMajority of patientsAdequate local controlCAR-T therapyPatterns of failurePET/CTMATERIAL/METHODSCommon regimens
2018
Radiation Therapy As a Bridging Strategy for Refractory Diffuse Large B Cell Lymphoma Patients Awaiting CAR T Manufacturing of Axicabtagene Ciloleucel
Jain M, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Liu H, Falchook A, Robinson T, Kim S, Locke F. Radiation Therapy As a Bridging Strategy for Refractory Diffuse Large B Cell Lymphoma Patients Awaiting CAR T Manufacturing of Axicabtagene Ciloleucel. Blood 2018, 132: 4220. DOI: 10.1182/blood-2018-99-117133.Peer-Reviewed Original ResearchCytokine release syndromeAxi-cel therapyCAR-T infusionCy conditioningCase seriesT infusionTumor burdenAxicabtagene ciloleucelCAR TSpeakers bureauRadiation therapyRefractory diffuse large B-cell lymphoma patientsRefractory diffuse large B-cell lymphomaChimeric antigen receptor T-cell therapyPatient experienced progressive diseaseSevere cytokine release syndromeDiffuse large B-cell lymphoma patientsDisease controlLarge B-cell lymphoma patientsB-cell lymphoma patientsDiffuse large B-cell lymphomaAdvisory CommitteeLarge B-cell lymphomaCAR T cell efficacyExperienced progressive disease